Pregnancy Risks With First Trimester GLP-1 Continuation - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Pregnancy Risks With First Trimester GLP-1 Continuation

Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.

  • By

  • Andrea Surnit

  • June 17, 2026

  • 3 min

Share

  • 1

    Continuation of GLP-1 receptor agonists in the first trimester does not show a clear increase in nonlive birth or major congenital malformations.

  • 2

    The study analyzed 3,572 pregnancies, comparing outcomes between those who continued GLP-1 treatment and those who did not.

  • 3

    The adjusted risk ratio for nonlive birth was 1.09, indicating no significant difference in risk between treatment groups.

  • 4

    Elective termination rates were higher among patients who continued GLP-1 treatment, potentially due to various influencing factors.

  • 5

    The study's observational design has limitations, including potential residual confounding and imprecise estimates for some outcomes.

Original Source(s)

Pregnancy Risks With First Trimester GLP-1 Continuation

  • by Andrea Surnit

  • June 17, 2026

Related Content

AI May Estimate Gestational Age

An adapted AI model estimated gestational age with accuracy comparable to the clinical standard when novice operators performed blind sweep ultrasonography in two clinical settings.

Availability of Rural Hospitals Providing Inpatient Maternity Care in Medicaid

Hospitals Say They Found a Tool To Help Reduce Childbirth Risks: Wristbands

“There are so many risks, and it’s just like you almost become invisible.”